Shen, R., Cao, W., Wang, L., Sheng, L., Zhang, Y., Wu, W., . . . Zhao, W. (2025). Response‐adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T‐cell therapy in relapsed/refractory large B‐cell lymphoma: A retrospective observational study. Wiley. https://doi.org/10.1002/ctm2.70310
Chicago Style (17th ed.) CitationShen, Rong, et al. Response‐adapted Zanubrutinib and Tislelizumab as a Potential Strategy to Enhance CD19 CAR T‐cell Therapy in Relapsed/refractory Large B‐cell Lymphoma: A Retrospective Observational Study. Wiley, 2025. https://doi.org/10.1002/ctm2.70310.
MLA (9th ed.) CitationShen, Rong, et al. Response‐adapted Zanubrutinib and Tislelizumab as a Potential Strategy to Enhance CD19 CAR T‐cell Therapy in Relapsed/refractory Large B‐cell Lymphoma: A Retrospective Observational Study. Wiley, 2025. https://doi.org/10.1002/ctm2.70310.